Aerie Pharmaceuticals Inc. (AERI) Sets New 52-Week High at $39.01
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $39.01 and last traded at $38.85, with a volume of 3,405,064 shares trading hands. The stock had previously closed at $38.58.
Several research firms have recently issued reports on AERI. HC Wainwright began coverage on Aerie Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $66.00 price objective for the company. RBC Capital Markets reaffirmed an “outperform” rating and issued a $55.00 price objective (up from $51.00) on shares of Aerie Pharmaceuticals in a research note on Friday, September 16th. Canaccord Genuity set a $50.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, September 14th. Brean Capital set a $48.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 15th. Finally, Stifel Nicolaus raised their price objective on Aerie Pharmaceuticals from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 15th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $49.40.
The stock’s market cap is $1.08 billion. The company has a 50-day moving average of $21.55 and a 200-day moving average of $17.27.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/aerie-pharmaceuticals-inc-aeri-sets-new-52-week-high-at-39-01.html
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. Analysts predict that Aerie Pharmaceuticals Inc. will post ($2.77) earnings per share for the current fiscal year.
In other news, major shareholder Foresite Capital Fund Ii, L.P. acquired 250,000 shares of the business’s stock in a transaction on Friday, July 22nd. The stock was bought at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 8.77% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of AERI. Barclays PLC boosted its position in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock valued at $106,000 after buying an additional 200 shares in the last quarter. BlackRock Advisors LLC boosted its position in shares of Aerie Pharmaceuticals by 15.0% in the second quarter. BlackRock Advisors LLC now owns 12,310 shares of the company’s stock valued at $217,000 after buying an additional 1,608 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Aerie Pharmaceuticals during the second quarter valued at $219,000. American International Group Inc. boosted its position in shares of Aerie Pharmaceuticals by 8.5% in the second quarter. American International Group Inc. now owns 13,864 shares of the company’s stock valued at $244,000 after buying an additional 1,082 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Aerie Pharmaceuticals by 17.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 15,900 shares of the company’s stock valued at $286,000 after buying an additional 2,400 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.